What is Foundayo (orforglipron)?
Foundayo is the brand name for orforglipron, Eli Lilly\'s first-in-class oral non-peptide GLP-1 receptor agonist. Approved by the FDA in March 2026 under the Commissioner\'s National Priority Voucher pilot, it represents a structural shift in GLP-1 delivery — moving from injectable peptides to small-molecule pills.
Why "non-peptide" matters
Peptide drugs (semaglutide, tirzepatide, retatrutide) are large molecules that don\'t survive the gut well — that\'s why they\'re injectable. Rybelsus (oral semaglutide) gets around this with a permeation enhancer (SNAC) that requires fasted administration with strict water-only rules. Orforglipron is a true small molecule (~500 Daltons vs semaglutide\'s ~4,100 Daltons) that\'s orally bioavailable without needing a permeation enhancer. The practical result: a once-daily pill with no food restrictions.
Efficacy: ATTAIN-1 results
ATTAIN-1 was Lilly\'s pivotal Phase 3 trial of orforglipron in adults with obesity without diabetes. Key results:
| Arm | Mean weight loss | Duration | ≥10% WL |
|---|---|---|---|
| Placebo | -2.3% | 36 weeks | 10.2% |
| Orforglipron 12 mg | -12.2% | 36 weeks | 56.8% |
| Orforglipron 36 mg | -14.7% | 36 weeks | 69.0% |
The 36 mg dose produced weight loss roughly comparable to injectable semaglutide 2.4 mg at 68 weeks in STEP-1, but in half the timeframe (36 vs 68 weeks). Longer-term data (72-104 weeks) is being collected in ATTAIN-2 extension.
Direct comparison: Foundayo vs compounded semaglutide
| Foundayo (orforglipron) | Compounded semaglutide | |
|---|---|---|
| Administration | Once-daily oral pill, no food restriction | Once-weekly subcutaneous injection |
| Mechanism | Small-molecule GLP-1 agonist | Peptide GLP-1 agonist |
| FDA status | Approved March 2026 | Not FDA-approved (compounded, under §503A/§503B) |
| Mean weight loss | -14.7% at 36 weeks | -14.9% at 68 weeks (STEP-1 reference) |
| Cash-pay cost | ~$800/mo (Lilly direct, early 2026) | $145-279/mo |
| Side effects | Nausea 32%, vomiting 11%, diarrhea 19% (36 mg) | Similar GI profile + possible injection-site reactions |
| Insurance coverage | Variable; Lilly direct cash channel available | Cash-pay only (HSA/FSA accepted) |
| Track record | Approved 3 months ago (limited post-market data) | Semaglutide approved 2021; 5+ years RWE |
Who should choose Foundayo over compounded semaglutide?
- Strong needle aversion: patients who can\'t or won\'t inject weekly
- Insurance covers it: if a commercial plan covers Foundayo at <$100/mo copay, the cost differential closes
- Preference for FDA-approved finished product: Foundayo is FDA-approved; compounded sema isn\'t
- Travel-frequent lifestyle: oral medication is simpler for travel than injection storage
Who should stick with compounded injectable semaglutide?
- Cost-conscious: $145/mo (NexLife 12-mo plan) vs ~$800/mo Foundayo cash-pay is a $7,800/year difference
- Already established on injectable: no compelling reason to switch if tolerating well
- Want maximum 1-year weight loss: injectable semaglutide titrated to 2.4 mg over 68 weeks may produce more total weight loss than Foundayo 36 mg over 36 weeks; awaiting ATTAIN-2 long-term data
- Compliance with weekly dosing: once-weekly is structurally easier for some patients than daily pills
What about Rybelsus (oral semaglutide)?
Rybelsus is FDA-approved for type 2 diabetes (not obesity) at 3-14 mg daily. It\'s a peptide formulation requiring strict fasted administration — take 30+ minutes before food/drink with only 4 oz water. Most patients find this inconvenient and prefer injectable Wegovy or Ozempic. Rybelsus is not generally compounded due to formulation complexity (SNAC permeation enhancer).
Outlook
Foundayo\'s approval marks the start of the oral-GLP-1 era. Lilly has additional Phase 3 trials reading out in 2027-2028 (ATTAIN-2 long-term, ATTAIN-3 cardiovascular outcomes). Other oral non-peptide GLP-1s are in earlier development (Pfizer\'s danuglipron, others). Pricing competition between branded oral and compounded injectable may emerge as the category matures — but in 2026, compounded injectable semaglutide remains the substantially lower-cost option for patients prioritizing affordability.